InflaRx announced plans to start two Phase 2 clinical trials in 2027 for izicopan, an oral C5a receptor inhibitor, targeting ANCA-associated vasculitis (AAV) with renal involvement. One trial will be placebo-controlled focusing on renal function, while another open-label study will explore replacing corticosteroids. Initial data are expected in 2028. The company projects izicopan's peak sales potential at $1.5 to $2 billion and is also exploring its use in other rare renal diseases. InflaRx has a strong cash position to fund operations through 2029 and is supported by an expert advisory board.
InflaRx's izicopan development plans provide context for readers interested in biopharmaceutical innovation. For readers following the health sector, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: of 150 priced health-sector US stocks tradable on Pluang, 74 rose and 69 fell today. Notable movers include ACB at USD 4.40 (+4.27%), TVTX at USD 47.30 (-3.98%), and BNTX at USD 90.10 (+2.94%) with 100% buy order activity on Pluang.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
